Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria
- PMID: 23902921
- PMCID: PMC4539010
- DOI: 10.1097/QAD.0b013e32835f1d68
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria
Abstract
In recent years, evidence has accumulated regarding the ability of HAART to prevent HIV transmission. Early supportive evidence was derived from observational, ecological and population-based studies. More recently, a randomized clinical trial showed that immediate use of HAART led to a 96% decrease in HIV transmission events within HIV serodiscordant heterosexual couples. However, the generalizability of the effect of HAART, and the population-level impact on HIV transmission continues to generate substantial debate. We, therefore, conducted a review of the evidence regarding the preventive effect of HAART on HIV transmission within the context of the Bradford Hill criteria for causality. Taken together, we find the accumulated evidence supporting HIV treatment as prevention meets each of the Bradford Hill criteria for causality. We conclude that the opportunity cost of inaction while waiting for additional evidence on the generalizability of effect in other risk groups is too high. Efforts should be redoubled to mobilize the financial capital and political will to optimize implementation of HIV Treatment as Prevention strategies on a wide scale.
Conflict of interest statement
P.C. has declared board membership for GSK/ViiV, Janssen and Merck; pending grants from Abbot, payments for lectures from GSK, Abbott, Janssen and Merck and payment for educational development presentations from ViiV. B.W. has declared WHO consultancy. J.L. declares grants from Abbott, Gilead, Johnson & Johnson, Merck and Mylan. J.M. has also received financial support from the International AIDS Society, United Nations AIDS Program, World Health Organization, National Institutes of Health Research-Office of AIDS Research, National Institute of Allergy & Infectious Diseases, The United States President’s Emergency Plan for AIDS Relief (PEPfAR), Bill & Melinda Gates Foundation, French National Agency for Research on AIDS & Viral Hepatitis (ANRS), the Public Health Agency of Canada, the University of British Columbia, Simon Fraser University, Providence Health Care and Vancouver Coastal Health Authority. He has received grants from Abbott, Biolytical, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare.
Comment in
-
Generalizability and scalability of HIV 'treatment as prevention'.AIDS. 2013 Sep 24;27(15):2493-4. doi: 10.1097/01.aids.0000432468.61626.d4. AIDS. 2013. PMID: 24029737 No abstract available.
References
-
- Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel International AIDS Society-USA. JAMA. 1996;276:146–154. - PubMed
-
- Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321–333. - PubMed
-
- Hogg RS, O’Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, Montaner JS. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294. - PubMed
-
- The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817–824. - PubMed
-
- Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–19. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical